Efficacy of doxorubicin-loaded graphene nanoplatform chemo-photothermal therapy versus photothermal therapy alone for breast cancer xenograft tumors: a meta-analysis.

Int J HyperthermiaJul 14, 2026 (epub)
Clinical ResearchOncology (Medical)

Hua-Wei Gao, Zhi-Hong Li, Yan Lu et al.

✦ AI-curated · Sources linked

In 30 seconds

This meta-analysis evaluated the efficacy of doxorubicin-loaded graphene nanoplatform chemo-photothermal therapy (CPT) versus photothermal therapy (PTT) alone in breast cancer xenograft models. The analysis included nine studies with 46 animals in each group, revealing a pooled standardized mean difference (SMD) of -2.20 (95% CI: -2.76 to -1.65, p < 0.0001), indicating significantly greater tumor volume suppression with CPT.

Key findings

  • The pooled SMD for tumor volume suppression was -2.20 (95% CI: -2.76 to -1.65, p < 0.0001).
  • No significant differences were found in subgroup analyses by cell line, graphene type, or publication period.
  • Sensitivity analyses yielded pooled SMDs ranging from -2.09 to -2.37.
  • Secondary endpoints showed limited reporting on survival, toxicity, and biodistribution.

Why it matters

The findings suggest that doxorubicin-loaded graphene nanoplatform CPT may offer enhanced tumor suppression compared to PTT alone, indicating potential for improved therapeutic strategies in breast cancer treatment. However, further studies are needed to assess long-term safety and efficacy.

Source

Published in Int J Hyperthermia. This summary was written by xxcode from the publication's abstract and metadata. It is not peer reviewed and is not a substitute for the original article. For clinical decisions, review the original publication.

ShareTelegramLinkedIn

AI-generated summaries may contain errors or omissions. Verify clinically important information with the original publication.

More in Oncology (Medical)

Clinical ResearchOncology (Medical)

Zamtocabtagene autoleucel, a tandem CD20-CD19-directed CAR T-cell therapy, for second line treatment of large B-cell lymphoma in patients ineligible for transplantation (DALY 2-EU): primary analysis of an open-label, multicentre, randomised phase 2 study.

DALY 2-EU was an open-label, multicentre, randomised phase 2 trial comparing tandem CD20-CD19-directed zamtocabtagene autoleucel (zamto-cel) with R-GemOx in adults with second-line relapsed or refractory large B-cell…

Lancet OncolOct 27, 2026Read summary
Clinical ResearchOncology (Medical)

Neoadjuvant short-course radiotherapy followed by camrelizumab and chemotherapy versus standard of care for locally advanced rectal cancer (UNION): a prespecified interim analysis of a multicentre, open-label, randomised, phase 3 trial.

UNION was a multicentre, open-label, randomised phase 3 trial at nine hospitals in China comparing neoadjuvant short-course radiotherapy followed by camrelizumab plus CAPOX with long-course chemoradiotherapy followed by…

Lancet OncolOct 25, 2026Read summary
Clinical ResearchHematology

Efficacy and safety of mitapivat in patients with sickle cell disease (RISE UP): a phase 3, double-blind, global, randomised, placebo-controlled trial.

RISE UP was a phase 3, double-blind, global, randomised, placebo-controlled trial conducted at 69 sites in 15 countries. It evaluated twice-daily mitapivat in patients older than 16 years with sickle cell disease…

LancetOct 24, 2026Read summary

Want this personalized?

Stop searching the literature. Choose what you follow and xxcode will build your personalized medical digest.

  • Your specialties
  • Your filters and thresholds
  • Clinical Research + Case Reports, tuned separately
  • Automatic weekly delivery
  • Audio and text

Prefer listening? Personalized audio digests are available with Pro.

Stay updated for free

Get the 3 most interesting publications in one specialty each week.

Weekly email. Unsubscribe anytime.